Allergy Diagnostics Market Size, Share And Growth Report 2035

(MENAFN- Quintile Reports) The Global Allergy Diagnostics Market was estimated at USD 7.09 billion in 2026 and is projected to reach USD 20.51 billion by 2035 , reflecting a robust CAGR of 12.2% over the forecast period from 2026 to 2035. The Allergy Diagnostics market report offers a comprehensive and nuanced view of the industry, moving beyond conventional analysis. It provides a thorough examination of the markets dynamics, encompassing a detailed exploration of the factors propelling growth, such as evolving economic conditions, advancements in technology, shifts in regulatory policies, and changes in consumer behavior. Furthermore, the report discusses the projected Compound Annual Growth Rate (CAGR), providing stakeholders with a clear understanding of the market's expected growth trajectory and offering data-driven insights into future market dynamics.
The Allergy Diagnostics market under analysis is characterized by dynamic growth and evolving trends that are reshaping the competitive landscape. With 2025 serving as the base year for this Allergy Diagnostics market study, recent data highlights a significant expansion driven by technological advancements, rising consumer demand, and a growing focus on innovation. Companies are refining their go-to-market (GTM) strategies to effectively capture these emerging opportunities and respond to the rapidly changing market dynamics.
Key trends influencing the Allergy Diagnostics market include the rapid adoption of digital technologies, the integration of sustainable practices, and the increasing importance of customer experience. These trends are not only driving growth but also creating new challenges for industry participants, who must adapt their GTM strategies to navigate regulatory changes, supply chain disruptions, and fluctuating economic conditions. Despite these challenges, the Allergy Diagnostics market is poised for sustained growth, with emerging markets playing a critical role in the expansion of the industry.
Looking ahead, the Allergy Diagnostics market is forecasted to continue its upward momentum through 2035, supported by ongoing investments in research and development, strategic partnerships, and mergers and acquisitions. Companies that can effectively tailor their GTM strategies to the evolving market landscape, innovate, and meet shifting consumer demands are likely to achieve sustained success. Allergy Diagnostics market report provides a comprehensive analysis of the current market environment and offers valuable insights into the key drivers, challenges, and opportunities that will shape the industry's future over the next decade. This report offers a comprehensive analysis of market dynamics across various segments, regions, and countries, incorporating both qualitative and quantitative data. It covers the period from 2017 to 2035, providing a detailed examination of historical performance, current market conditions, and future projections.
Historical Analysis (2017-2024): The report presents a thorough review of market trends, performance metrics, and growth trajectories for the years 2017 through 2024. This historical perspective is crucial for understanding past market behavior and identifying patterns that influence current and future market dynamics.
Forecast and Projections (2026-2035) : Building on historical data, the report provides forward-looking insights, including market forecasts and growth projections from 2026 to 2035. It details anticipated market trends, emerging opportunities, and potential challenges across different segments, regions, and countries.
Compound Annual Growth Rate (CAGR): The report includes a precise calculation of the compound annual growth rate (CAGR) for the forecast period of 2026 to 2035. This metric will be instrumental in assessing the expected growth trajectory and the overall market potential during the forecast period.

Allergy Diagnostics Market

The allergy diagnostics market is the global industry focused on creating, producing, and distributing tools, assays, and systems to identify specific allergens that cause hypersensitivity reactions in patients. These diagnostic tools include in vivo testing methods like skin prick tests and intradermal tests, as well as in vitro assays such as immunoassays (ELISA, ImmunoCAP), specific IgE testing, and molecular allergen diagnostics.

The market serves allergists, immunologists, diagnostic laboratories, hospitals, research institutes, and point-of-care testing providers. As food allergies, respiratory allergies, and skin-related hypersensitivities become more common, the market is changing quickly to offer faster, more accurate, and less invasive testing solutions. The integration of digital health and multiplex testing platforms is also speeding up market adoption in clinical environments.

What are the drivers of allergy diagnostics market

• A key driver of this market is the increasing global burden of allergic diseases up to 3040% of the global population is now affected by at least one allergic condition.
• Rising air pollution, urbanization, dietary changes, and exposure to novel allergens have led to significant growth in diagnostic demand.
• Increased awareness among healthcare providers and patients about early allergy detection is leading to greater utilization of in vitro and in vivo testing.
• Technological advancements, particularly in multiplex molecular testing and component-resolved diagnostics, enable accurate identification of specific allergen molecules, improving diagnostic precision and treatment personalization.
• The growing demand for allergy testing in pediatrics, occupational medicine, and preventive care, combined with rising adoption of automation and digital platforms in laboratories, is boosting diagnostic throughput and efficiency.
• Rising consumer preference for personalized and preventive health solutions. Individuals are increasingly opting for diagnostic screening to understand food intolerances, respiratory sensitivities, and skin reactivity as part of proactive health management.
• The growth of direct-to-consumer testing kits and tele-diagnostics platforms is making allergy testing more accessible and appealing to a broader population.

What are the challenges and restraining factors of allergy diagnostics market

• One major challenge is the high cost of advanced allergy testing, especially molecular diagnostics and multiplex assays, which limits accessibility in low-income and developing regions.
• Many allergy tests remain uncovered or partially reimbursed in public health systems, leading to out-of-pocket expenses for patients.
• Variability in test accuracy, particularly among skin tests and over-the-counter kits, can lead to false positives or underdiagnosis, thereby affecting clinical decisions.
• Standardization across laboratories remains inconsistent, impacting result reliability.
• Another limitation is the shortage of trained allergists and immunologists in many countries, resulting in delays in proper diagnosis and care.
• In rural or underserved areas, lack of access to allergy testing facilities poses a significant barrier to early detection.
• Stringent regulatory frameworks for diagnostic devices, especially for new molecular platforms, and the time-consuming process of gaining clinical validation and approvals can also delay commercialization and market entry.

What are the regional trends of allergy diagnostics market

North America holds a leading share in the allergy diagnostics market, driven by high allergy prevalence, advanced healthcare systems, and the presence of major diagnostic players. The U.S. benefits from established reimbursement pathways and wide adoption of both laboratory-based and point-of-care allergy tests.

Europe is a well-established market with strong demand for allergy diagnostics in countries like Germany, France, Italy, and the U.K. Public health initiatives promoting early allergy detection, combined with widespread use of specific IgE testing and component-resolved diagnostics, are boosting growth.

Asia Pacific is emerging as a high-growth region due to rising awareness, increasing pediatric allergy cases, and expanding laboratory infrastructure. Japan and South Korea are investing in clinical-grade testing, while India and China are seeing demand for cost-effective and high-throughput diagnostic platforms.

Latin America is gradually adopting allergy diagnostics, especially in urban centers in Brazil, Mexico, and Argentina. Government health programs addressing asthma and respiratory allergies are fostering increased diagnostic uptake, though rural coverage remains limited.

Middle East & Africa are in the early stages of allergy diagnostics adoption. The UAE and Saudi Arabia are investing in allergy testing through public-private partnerships and diagnostic expansions, while parts of Africa rely on donor-supported health screening and mobile lab programs.

Country-Wise Outlook:

• U.S. strengthens allergy detection through clinical integration and innovation-driven diagnostics: The United States continues to lead the global allergy diagnostics market, supported by high prevalence of allergic rhinitis affecting over 50 million Americans annuallyand widespread clinical adoption of both skin and serological testing methods. Diagnostic services are well-integrated into primary care, pediatrics, and pulmonology practices, allowing for routine allergy evaluation and follow-up care.
• Consumer demand for personalized health data has driven the rise of direct-to-consumer allergy test kits and digital interpretation tools, often linked with telehealth consultations. At the clinical level, adoption of molecular allergen testing and component-resolved diagnostics is expanding, particularly in specialized allergy and immunology clinics.
• Germany leads with multiplex testing and structured lab systems: Germany is a front-runner in Europe for allergy diagnostics, with strong adoption of component-resolved testing and automated immunoassays in hospital and outpatient labs. Health insurers support routine allergy screening, especially for pediatric patients and asthma sufferers.
• National quality control programs and established lab infrastructure have enabled high diagnostic accuracy and efficiency. German manufacturers and research bodies are also contributing to allergen standardization and innovation in environmental exposure profiling.
• Japan advances allergy testing for urban pediatric populations: Japan has witnessed rising allergy cases, especially food and respiratory allergies in children. Its healthcare system supports allergy diagnostics through insurance coverage and regular school-based health checks.
• The country is investing in multiplex testing panels, molecular allergen platforms, and AI-based analysis for faster, non-invasive allergy profiling. Japanese research institutions are also studying unique regional allergens to develop localized diagnostics tailored for urban populations and dietary exposures.

Competitive Analysis:

Companies are differentiating by developing multiplex immunoassay platforms, component-resolved diagnostics, and microarray-based allergy panels that improve sensitivity and specificity. Point-of-care devices and lab-automation-compatible systems are gaining traction.

Market participants are forming partnerships with hospitals, research centers, and digital health startups to expand access to testing. Regional distribution networks and regulatory approvals are crucial for tapping into Asia and Latin America.

Integration of allergy diagnostics with EHRs, predictive risk models, and mobile health apps allows personalized recommendations and allergy tracking. Players offering AI-based analytics and cloud-reporting platforms are securing a competitive edge.

Product portfolios are expanding to address pediatric allergy testing, occupational exposure profiling, and food-specific allergen diagnostics. Firms with validated kits for a wide range of allergen sources (pollen, food, dust mites, animal dander) are gaining preference.

Key players in the market are bioMerieux SA, Siemens Healthineers, Thermo Fisher Scientific, Danaher Corporation, Omega Diagnostics Group, Stallergenes Greer, Eurofins Scientific, EUROIMMUN Medizinische Labordiagnostika, Abionic SA, HYCOR Biomedical, Lincoln Diagnostics, Neogen Corporation, Romer Labs Division, Minaris Medical America, Inc., HollisterStier Allergy, and other players.
Recent Development:

• In July 2024, AliveDx has successfully obtained the IVDR CE mark for its innovative microarray immunoassay, developed to detect specific IgE antibodies targeting protein allergens in human serum. This marks the companys first entry into allergy diagnostics, expanding its product offerings beyond the autoimmunity segment.
• In October 2024, Polyrizon Ltd. has entered into a manufacturing agreement with Eurofins CDMO for the production of Clinical Trial Material (CTM) related to its PL-14 allergy blocker.

MENAFN26082025007836016821ID1109979793